• Biosimilars
  • Drug Development/R&D
  • All Topics
OHE OHE
Newsletter SignupSubscribe

News & Insights
  • News
  • Events
  • Insights
  • Bulletin
  • News
  • Events
  • Insights
  • Bulletin

News & Insights

  • News
  • Events
  • Insights
  • Bulletin
Newsletter SignupSubscribe
  • News
  • Events
  • Insights
  • Bulletin

Close
OHE OHE
  • Research & Publications
  • News & Insights
  • Education
  • Innovation Policy Prize
  • Events
  • About Us
  • OHE Experts
  • Contact Us
Newsletter SignupSubscribe

Research & Publications

All Publications

Filter by:
  • Antimicrobial Resistance (AMR)
  • Biosimilars
  • Cell and Gene Therapies
  • Chronic Diseases
  • Combination Therapies
  • COVID-19 Research
  • Digital Health
  • Drug Development/R&D
  • Emerging Markets
  • EQ-5D and PROMs
  • Health Care Systems
  • Health Data and Statistics
  • Health Technology Assessment
  • Precision Medicine
  • Real World Evidence
  • Use of Medicines
  • Value-Based Pricing
  • Vaccine Research
  • Economics of Innovation
  • Measuring and Valuing Outcomes
  • Policy, Organisation and Incentives in Health Systems
  • Value, Affordability and Decision Making

News & Insights

  • News
  • Events
  • Insights
  • Bulletin

Education

  • Education Hub
  • OHE Graduate School
  • EVIA Programme

Innovation Policy Prize

  • The Prize Fund
  • 2022 Prize Fund

Latest Research & Publications

Proposal for a General Outcome-based Value Attribution Framework for Combination Therapies

CombTher_Adobe_photoguns_portrait
Read more
© photoguns
  • Digital Health

Navigating the Landscape of Digital Health – United Kingdom

Healthcare_Adobe_elenabsl
Read more

2021 OHE Annual Report to the Charity Commission

charityreport_lina-trochez-unsplash_landscape
Read more
© Lina Trochez/Unsplash

Supporting the Era of Green Pharmaceuticals in the UK

Sustainability_AdobeStock_270582392_landscape
Read more

Quality of life and wellbeing in individuals with experience of fertility problems and assisted reproductive techniques

Quality of life assisted reproduction Cover
Read more
  • Cell and Gene Therapies
  • Value, Affordability, and…

Health Technology Assessment of Gene Therapies: Are Our Methods Fit for Purpose?

gene_therapies_national-cancer-institute-unsplash_landscape
Read more
© NCI/Unsplash
  • Drug Development/R&D
  • Economics of Innovation
  • Health Policy and Regulation

Limitations of CBO’s Simulation Model of New Drug Development as a Tool for Policymakers

CBO-US_mayer-tawfik-K4Ckc0AxgDI-unsplash_landscape
Read more
© Mayer Tawfik/Unsplash
  • Measuring and Valuing Outcomes

When Generic Measures Fail to Reflect What Matters to Patients: Three Case Studies

PROMS_unsplash_National Cancer Institute_landscape
Read more
© NCI/Unsplash
Close
OHE
  • All Publications

    Filter by:
    • Antimicrobial Resistance (AMR)
    • Biosimilars
    • Cell and Gene Therapies
    • Chronic Diseases
    • Combination Therapies
    • COVID-19 Research
    • Digital Health
    • Drug Development/R&D
    • Emerging Markets
    • EQ-5D and PROMs
    • Health Care Systems
    • Health Data and Statistics
    • Health Technology Assessment
    • Precision Medicine
    • Real World Evidence
    • Use of Medicines
    • Value-Based Pricing
    • Vaccine Research
    • Economics of Innovation
    • Measuring and Valuing Outcomes
    • Policy, Organisation and Incentives in Health Systems
    • Value, Affordability and Decision Making
    • News
    • Events
    • Insights
    • Bulletin
    • Education Hub
    • OHE Graduate School
    • EVIA Programme
    • The Prize Fund
    • 2022 Prize Fund
  • Events
  • About Us
  • OHE Experts
  • Contact Us
Newsletter SignupSubscribe
Back
  • News
11 min read 31st January 2018

Comparing Preference-based Outcome Measures for Overactive Bladder: EQ-5D-5L vs OAB-5D

A recent paper examines EQ-5D-5L outcomes in patients with overactive bladder and compares them to results on the OAB-5D, a condition-specific measure. A new journal article by OHE’s Michael Herdman and Nancy Devlin and colleagues was recently published in The Patient.…

Share:
  •  Twitter
  •  LinkedIn
  •  Facebook
  • has-icon Email

A recent paper examines EQ-5D-5L outcomes in patients with overactive bladder and compares them to results on the OAB-5D, a condition-specific measure.

A new journal article by OHE’s Michael Herdman and Nancy Devlin and colleagues was recently published in The Patient. The paper examines EQ-5D-5L outcomes from a clinical trial in patients with overactive bladder (OAB) and compares them to results on the OAB-5D, a condition-specific preference-based measure (PBM) of health.

Cost-utility analysis forms an integral part of health technology assessment (HTA) in a growing number of countries. Societal preferences for the health states associated with a given health condition before and after treatment are an essential component of such analyses and are often derived using preference-based measures of health such as EQ-5D.

Increasingly, condition-specific PBMs are becoming available, which may offer advantages over more generic PBMs such as EQ-5D. One such measure is the OAB-5D, which is derived from the Overactive Bladder Questionnaire (OAB-q) and which assesses health dimensions that are particularly pertinent to patients with OAB. There is little information available, however, about the comparative performance of the two PBMs in patients with OAB.

Our new paper compares outcomes on EQ-5D-5L with those on the OAB-5D using data from a clinical trial in which the two instruments were administered. The paper is authored by OHE’s Michael Herdman, and Nancy Devlin, in collaboration with researchers from Astellas Pharma Europe, the European Foundation for the study of Chronic Liver Failure, Alliance Urology Specialists in the US, and the University of Bristol and Bristol Urological Institute, in the UK.

Data were from the BESIDE clinical trial, which compared outcomes in patients with OAB randomised to one of three different treatment regimens (combination treatment with solifenacin 5 mg plus mirabegron, solifenacin 5 mg, or solifenacin 10 mg). EQ-5D-5L and OAB-q (from which OAB-5D scores were derived) were administered at baseline and at weeks 4, 8, 12 and end of treatment. A particularly relevant aspect of the analysis is that EQ-5D-5L preference weights were calculated using the recently published EQ-5D-5L value set for England, making this one of the first published analyses to be carried out using the new value set.

In the 2,054 patients who received at least one dose of treatment over the study period, EQ-5D-5L Index mean score changes from baseline to end of treatment were observed to be larger with combination treatment (0.059) than with monotherapy (changes with solifenacin 5 mg and 10 mg of 0.040 and 0.044, respectively), but the differences were not statistically significant. Using the OAB-5D, on the other hand, it was found that differences in the size of improvements between arms were statistically significant (mean change of 0.107 for combination treatment vs 0.085 for 5 mg, and 0.087 for 10 mg; p ≤ 0.01), indicating that the condition-specific measure was more sensitive to treatment differences than the generic measure. The dimensions most improved overall were anxiety/depression, pain/discomfort, and usual activities on EQ-5D-5L, and urge, urine loss, and coping on OAB-5D.

In conclusion, the authors suggested that using both a generic and condition-specific PBMs in the same study could provide the optimal measurement strategy for cost-utility analysis in this population. Use of the condition-specific measure enhances measurement precision and sensitivity, and content relevance, whilst the generic measure permits comparisons with outcomes from other studies, treatments, and populations.

Herdman, M., Nazir, J., Hakimi, J., Siddiqui, E., Huang, M., Pavesi, M., MacDiamid, S., Drake, M.J., and Devlin, N. 2017. Assessing Preference-Based Outcome Measures for Overactive Bladder: An Evaluation of Patient-Reported Outcome Data from the BESIDE Clinical Trial. Patient, 10 (6):677-86. DOI | PubMed | RePEc

  • EQ-5D and PROMs
  • Measuring and Valuing Outcomes
  • External Publications

Related News

  • News
  • September 2020

Establishing a Reasonable Price for an Orphan Drug

Read more
  • News
  • April 2020

Augmenting Cost-Effectiveness Analysis for Uncertainty: The Implications for Value Assessment—Rationale and Empirical Support

Read more
  • News
  • April 2020

Financing and Scaling Innovation for the COVID Fight: A Closer Look at Demand-Side Incentives for a Vaccine

Read more
  • News
  • February 2020

Unpacking the Black Box of Payer Policy: A Demand-Side Approach for Equitable Uptake of Cost-Effective Health Innovation

Read more
footer_ohe_logo

Leading intellectual authority on global health economics

Sign Up for the OHE News Bulletin

Newsletter SignupStart Sign Up

Research & Publications

News & Insights

Innovation Policy Prize

Education

Events

About Us

OHE Experts

Contact Us

Sign Up for the OHE News Bulletin

Newsletter SignupStart Sign Up

The Office of Health Economics (OHE) is a company limited by guarantee registered in England and Wales (registered number 09848965) and its registered office is at 2nd Floor Goldings House, Hay’s Galleria, 2 Hay’s Lane, London, SE1 2HB.

Terms & Conditions

Privacy Policy

Cookies Policy

© 2023 Website Design

An error has occurred, please try again later.An error has occurred, please try again later.

We are using cookies to give you the best experience on our website.

You can find out more about which cookies we are using or switch them off in settings.

 Twitter
 Facebook
 LinkedIn
 Copy
 Email
Powered by  GDPR Cookie Compliance
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.

Strictly Necessary Cookies

Strictly Necessary Cookie should be enabled at all times so that we can save your preferences for cookie settings.

If you disable this cookie, we will not be able to save your preferences. This means that every time you visit this website you will need to enable or disable cookies again.

3rd Party Cookies

This website uses Google Analytics to collect anonymous information such as the number of visitors to the site, and the most popular pages.

Keeping this cookie enabled helps us to improve our website.

Please enable Strictly Necessary Cookies first so that we can save your preferences!